01—Abstract
Summary
Summary of the 8-K filed May 18, 2026. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific (NYSE: BSX) disclosed in an 8-K filed May 18, 2026 that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association, paying $2 billiona of its common stock under its previously announced $5 billion buyback authorization.
Under the ASR, the company will receive initial delivery of shares worth 80% of the $2 billionb, or approximately 30.4 million shares based on the May 15, 2026 closing price of $52.68. The final number of shares repurchased will depend on the volume-weighted average price during the ASR term, less a discount and subject to contractual adjustments, with final settlement expected by June 30, 2026. For investors, the transaction signals management's confidence in the company's valuation and its capacity to return capital while maintaining flexibility for other uses.
Upon completion, roughly $3 billionc will remain under the repurchase authorization. Management estimates the ASR will be accretive to adjusted EPS by $0.02 in full-year 2026, relative to guidance issued April 22, 2026.
The filing is largely an announcement of a capital allocation action rather than a change in operating results. Investors should note that the final share count is not yet fixed, and that the forward-looking statements flag risks including competition, regulatory and reimbursement conditions, supply chain issues, clinical trial outcomes, and litigation.
02—Key points
Key Highlights
- $2 billion accelerated share repurchase (ASR) agreement executed with JPMorgan Chase Bank, N.A., drawn from a $5 billion authorization
- Initial delivery of approximately 30.4 million shares, based on 80% of the $2 billion repurchase price and the May 15, 2026 close of $52.68
- Final share count is variable, determined by the VWAP over the ASR term less a discount, and subject to contractual adjustments
- Final settlement expected by June 30, 2026
- Approximately $3 billion remains available under the repurchase authorization after completion
- Management estimates a $0.02 accretion to full-year 2026 adjusted EPS versus April 22, 2026 guidance
- Filing is an 8.01 Other Event disclosure; no changes to reported financial results or operating metrics were included
03—Questions
Frequently Asked Questions
How many shares will Boston Scientific actually repurchase under the ASR?
Boston Scientific initially receives about 30.4 million shares, worth 80% of the $2 billion price at the May 15, 2026 close of $52.68. The final total will be set by the volume-weighted average price over the ASR term, less a discount and subject to the agreement's adjustments, so the ultimate count is not yet known from the filing.
Why does this buyback matter for EPS?
Repurchasing shares reduces the diluted share count, which lifts per-share earnings. The company estimates the ASR will add $0.02 to 2026 adjusted EPS, above its April 22, 2026 guidance, though this is a modest effect relative to the company's overall earnings base.
When will the ASR be completed?
Final settlement is expected by June 30, 2026. At settlement, the final share count will be reconciled against the VWAP-based calculation.
How much authorization remains after this transaction?
Following completion of the ASR, Boston Scientific will have $3 billion remaining under its $5 billion share repurchase authorization.
Does this filing reveal anything about Boston Scientific's operating performance?
No. The 8-K covers only the ASR and the related share repurchase authorization. It contains no new financial results, guidance changes beyond the EPS accretion estimate, or operational updates, so investors should refer to the company's periodic reports and earnings materials for performance details.
04—Continue